lobbying_activities: 3375867

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3375867 f0f4bac9-f255-48cb-a50f-0a9666ec0ff5 Q2 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2025 second_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-07-01T16:22:34-04:00